ASP Isotopes extends Renergen acquisition deadline to Jan 30, 2026; awaits FinSurv approval
ASP Isotopes Inc.
Longstop date for Renergen acquisition extended to Jan 30, 2026 to allow time for remaining regulatory conditions.
Remaining key condition: approval from the South African Reserve Bank's Financial Surveillance Department (FinSurv).
Previously received approvals: Competition Commission, Industrial Development Corporation of South Africa, and U.S. International Development Finance Corporation.
ASPI also extended the loan repayment date from Renergen under the Term Loan Facility Agreement to Jan 30, 2026.
Extracted from this filing and checked against the source text.
Material AgreementsSEC 8-K Item 1.01/1.02confidence 0.9
ASP Isotopes Inc. amended a credit facility with Renergen (effective 2025-11-27).
Action
amendment
Agreement
credit facility
Counterparty
Renergen
Effective
2025-11-27
Exact text from the filing
on November 27, 2025, the Company, ASP Isotopes South Africa Proprietary Limited (“ASPI South Africa”) and Renergen entered into an amendment to the Term Loan Facility Agreement, dated May 19, 2025, by and among the Company, ASP Isotopes South Africa, as lender, and Renergen, as borrower, to extend the final repayment date thereunder to January 30, 2026.
Material AgreementsSEC 8-K Item 1.01/1.02confidence 0.9
ASP Isotopes Inc. amended a merger with Renergen Limited (effective 2025-11-27).
Action
amendment
Agreement
merger
Counterparty
Renergen Limited
Effective
2025-11-27
Exact text from the filing
On November 27, 2025, ASP Isotopes Inc. (the “Company” or “ASP Isotopes”) and Renergen Limited (“Renergen”), a South African company listed on the exchange operated by the JSE Limited and the Australian Securities Exchange, entered into a letter agreement to extend the date for the fulfillment of the conditions to the previously announced offer by the Company to acquire 100% of the ordinary shares (excluding treasury shares) of Renergen, pursuant to a scheme of arrangement under South African law pursuant to which Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date (the “Scheme”).
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.